Annexon reports inducement grant to new employee under nasdaq listing rule 5635(c)(4)

Brisbane, calif., feb. 20, 2024 (globe newswire) -- annexon, inc. (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 employment inducement award plan. the equity award was approved on february 16, 2024, in accordance with nasdaq listing rule 5635(c)(4).
ANNX Ratings Summary
ANNX Quant Ranking